SNJ Pharma Inc. (SNJ) was founded to revolutionize the treatment of thrombotic disorders with SNJ101, the first plasmin-independent thrombolytic agent.
We are determined to overcome the limitations of current FDA- approved tPA and TNK therapies by eliminating their associated bleeding complications and providing a new treatment option for patients suffering from thrombotic episodes.
SNJ Pharma was established in 2020 by Dr. Hyeon Kim, inventor of the patent for SNJ101, at Biolabs Los Angeles, located within the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
The company’s portfolio, which includes SNJ101 for thrombolysis, aims to address unmet medical needs related to severe thrombotic and thromboembolic conditions, with a focus on improved safety and decreased side effects.